Novo Nordisk to slash prices of weightloss drugs in US / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File
RBGPF
-13.5000
The China Mail - Novo Nordisk to slash prices of weightloss drugs in US
USD
-
AED 3.672501
AFN 63.501996
ALL 81.529489
AMD 375.111005
ANG 1.789884
AOA 917.999429
ARS 1378.523604
AUD 1.397917
AWG 1.8
AZN 1.700244
BAM 1.670018
BBD 2.021074
BDT 123.120931
BGN 1.668102
BHD 0.377212
BIF 2983.85754
BMD 1
BND 1.277223
BOB 6.933593
BRL 4.968599
BSD 1.003407
BTN 94.06767
BWP 13.491474
BYN 2.823304
BYR 19600
BZD 2.018171
CAD 1.366802
CDF 2310.999669
CHF 0.785097
CLF 0.022619
CLP 890.229815
CNY 6.824799
CNH 6.833425
COP 3571.47
CRC 457.171157
CUC 1
CUP 26.5
CVE 94.15346
CZK 20.80635
DJF 178.685179
DKK 6.383655
DOP 60.386896
DZD 132.512995
EGP 51.999482
ERN 15
ETB 157.950756
EUR 0.85425
FJD 2.217902
FKP 0.740532
GBP 0.741245
GEL 2.69013
GGP 0.740532
GHS 11.10817
GIP 0.740532
GMD 73.00022
GNF 8806.991628
GTQ 7.669581
GYD 209.952866
HKD 7.83231
HNL 26.659209
HRK 6.4376
HTG 131.351211
HUF 311.80799
IDR 17286.8
ILS 3.00559
IMP 0.740532
INR 94.047499
IQD 1314.468201
IRR 1319500.000189
ISK 122.840209
JEP 0.740532
JMD 158.959624
JOD 0.70899
JPY 159.553955
KES 129.149781
KGS 87.427401
KHR 4016.616359
KMF 421.00028
KPW 899.95002
KRW 1480.910083
KWD 0.30808
KYD 0.836208
KZT 464.965162
LAK 22138.636519
LBP 89858.937248
LKR 318.857162
LRD 184.634433
LSL 16.494808
LTL 2.95274
LVL 0.60489
LYD 6.345262
MAD 9.265398
MDL 17.188821
MGA 4161.845762
MKD 52.678579
MMK 2099.761028
MNT 3579.096956
MOP 8.094644
MRU 40.057552
MUR 46.74025
MVR 15.449665
MWK 1739.624204
MXN 17.34975
MYR 3.965497
MZN 63.910124
NAD 16.494808
NGN 1351.590305
NIO 36.930302
NOK 9.30164
NPR 150.509557
NZD 1.698215
OMR 0.3845
PAB 1.003488
PEN 3.448364
PGK 4.413987
PHP 60.424499
PKR 279.73666
PLN 3.62613
PYG 6311.960448
QAR 3.658464
RON 4.350301
RSD 100.242031
RUB 75.100648
RWF 1466.294941
SAR 3.750609
SBD 8.048395
SCR 14.13904
SDG 600.500392
SEK 9.226705
SGD 1.276355
SHP 0.746601
SLE 24.649815
SLL 20969.496166
SOS 573.470581
SRD 37.458014
STD 20697.981008
STN 20.921395
SVC 8.780484
SYP 110.632441
SZL 16.48863
THB 32.385499
TJS 9.447326
TMT 3.505
TND 2.91772
TOP 2.40776
TRY 44.924502
TTD 6.80289
TWD 31.544503
TZS 2595.000256
UAH 44.026505
UGX 3717.808593
UYU 39.893265
UZS 12170.349023
VES 482.15515
VND 26328
VUV 118.032476
WST 2.725399
XAF 560.113225
XAG 0.013156
XAU 0.000212
XCD 2.70255
XCG 1.80844
XDR 0.696601
XOF 560.115617
XPF 101.833707
YER 238.650268
ZAR 16.50625
ZMK 9001.197612
ZMW 19.090436
ZWL 321.999592
- Iran says won't reopen Hormuz if US upholds naval blockade
- Japanese team with school coach to cap remarkable journey to the top
- UN leadership hopefuls stress need for peace and restoring confidence
- France must avoid becoming 'hostage' on critical minerals: trade minister
- Thunder roll past Suns, Pistons bounce back to level series with Magic
- US says China used 'intimidation' to block Taiwan leader's Africa trip
- Suarez off mark but Messi fires blanks as Miami beat Salt Lake
- Inter ready to pounce for Serie A title glory as Milan host Juve
- Fresh paint, careful choreography as pope visits African prison
- Jones calls on Australian fans to get behind Japan at World Cup
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
C.Smith--ThChM
